Guided Therapeutics (GTHP) EBT Margin (2010 - 2025)
Guided Therapeutics (GTHP) posted EBT Margin of 206.44% for Q4 2025, up 83.31% sequentially from 1236.67% in Q3 2025, and up 6499356.0% YoY from N/an in Q4 2024.
Guided Therapeutics (GTHP) EBT Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics has reported EBT Margin for 16 years, with the latest figure at 206.44% in Q4 2025.
- Quarterly EBT Margin rose 6499356.0% year-over-year to 206.44% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 416.95% (up 3411162.0% YoY) and the FY2025 annual result came in at 416.69%, up 3411188.0% from the prior year.
- EBT Margin advanced to 206.44% in Q4 2025 per GTHP's latest filing, from 1236.67% in the prior quarter.
- Over five years, EBT Margin peaked at 357.89% in Q3 2021 and troughed at 65200.0% in Q4 2024.
- A 5-year average of 14300.47% and a median of 3744.32% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin slumped 6399375 bps in 2024, then surged 6499356 bps in 2025.
- Over 5 years, EBT Margin stood at 740.0% in 2021, then slumped by 4864 bps to 36733.33% in 2022, then surged by 97 bps to 1206.25% in 2023, then tumbled by 5305 bps to 65200.0% in 2024, then soared by 100 bps to 206.44% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 206.44%, 1236.67%, and 693.16% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 12.10% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 23.74% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 19.48% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 29.86% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 24.27% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 13.09% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 8.91% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 18.32% |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -206.44% |
| Sep 30, 2025 | -1,236.67% |
| Jun 30, 2025 | -693.16% |
| Dec 31, 2024 | -65,200.00% |
| Mar 31, 2024 | -6,700.00% |
| Dec 31, 2023 | -1,206.25% |
| Jun 30, 2023 | -3,538.64% |
| Mar 31, 2023 | -3,950.00% |
| Sep 30, 2022 | -36,733.33% |
| Jun 30, 2022 | -18,520.00% |
| Mar 31, 2022 | -10,140.00% |
| Dec 31, 2021 | -740.00% |
| Sep 30, 2021 | 357.89% |
| Jun 30, 2021 | -51,700.00% |
| Dec 31, 2020 | 8,664.00% |
| Sep 30, 2020 | 2,045.45% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -266,300.00% |
| Mar 31, 2019 | -1,194.44% |